DCM
CTMX icon

Driehaus Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Driehaus Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-290,415
Closed -$4.5M – 497
2017
Q2 		$4.5M Sell
290,415
-4,279
-1% -$64.5K 0.17% 143
2017
Q1 		$5.09M Buy
+294,694
New +$3.88M 0.17% 136

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Driehaus Capital Management's CTMX Position: Q3 2017 in Review

Driehaus Capital Management sold out of CytomX Therapeutics (CTMX) in Q3 2017, closing a stake of 290,415 shares — an estimated $4.5M sold.

Driehaus Capital Management first reported a position in CTMX in Q1 2017 and held it in 2 quarters. The position peaked at $5.09M in Q1 2017. 97 funds tracked by Wall St. Rank hold CTMX as of Q3 2017.

  • Driehaus Capital Management reported no remaining CytomX Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Driehaus Capital Management sold 290,415 CytomX Therapeutics shares in Q3 2017, an estimated $4.5M.
  • Driehaus Capital Management first reported a position in CytomX Therapeutics in Q1 2017 and held it in 2 quarters.
  • Driehaus Capital Management's CytomX Therapeutics position peaked at $5.09M in Q1 2017.
  • 97 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2017.

Based on Driehaus Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.